The Solo‐test Driver panel has the potential to identify an additional 18.3%, 16.5%, and 8.7% of RAS+ colorectal, PIK3CA+ breast, and EGFR+ lung cancer patients, respectively, when compared to FDA‐approved PCR tests. This evidence concerns the gene PIK3CA and lung carcinoma.